Renaissance Capital logo

Prevail Therapeutics Scheduled, Nasdaq: PRVL

Early stage biotech developing gene therapies for neurodegenerative diseases.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a gene therapy company leveraging breakthroughs in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. We are applying a precision medicine approach to neurodegeneration by studying our gene therapies in genetically defined patient populations. We believe this will increase the probability of creating disease-modifying therapies that improve patients’ lives. Our lead program is PR001 for the treatment of PD-GBA and neuronopathic Gaucher disease. We are focused on developing a broad pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of FTD-GRN and PR004 for the treatment of synucleinopathies.
more less
IPO News for Prevail Therapeutics
more
IPO Data
IPO File Date 05/24/2019
Offer Price
Price Range $16.00 - $18.00
Offer Shares (mm) 7.4
Deal Size ($mm) $125
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date
Offer Price
Price Range $16.00 - $18.00
Offer Shares (mm) 7.4
Deal Size ($mm) $125
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2017
Employees 33
Website www.prevailtherapeutics.com